With shares of Merck (NYSE:MRK) trading at around $47.56, is MRK an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
C = Catalyst for the Stock’s Movement
An FDA panel recently voted for approval of Suvorexant (insomnia). This doesn’t guarantee FDA approval, but increase the odds of approval. A decision is expected within a few months. Suvorexant’s potential is high. However, it hasn’t been all good news for Merck.
Singulair (asthma) Q1 sales declined 75 percent year-over-year due to patent expiration and competition from more affordable generic drugs. Maxalt (migraines) has also seen a drop in sales due to the ever-increasing threat of generics, and Temodar (brain cancer) is likely to see competition from generics. Another negative for Merck was that Phase III studies didn’t show enough efficacy for Merck to pursue regulatory filings for Preladenant (Parkinson’s). Other negatives include a revenue decline last year, a year-over-year revenue decline of 9 percent last quarter, a year-over-year earnings decline of 8.30 percent last quarter, and weak guidance.
Top Low Price Stocks To Invest In Right Now: Synopsys Inc (SNPS)
Synopsys, Inc., incorporated in 1986, is engaged in providing technology solutions used to develop electronics and electronic systems. It supplies the electronic design automation (EDA) software that engineers use to design, create prototypes for and test integrated circuits, also known as chips. It also supplies software and hardware used to develop the systems that incorporate integrated circuits and the software that runs on those integrated circuits. Its intellectual property (IP) products are pre-designed circuits that engineers use as components of larger chip designs rather than redesigning those circuits themselves. It also provides technical services to support its solutions and it help its customers develop chips and electronic systems. Its products and services are organized into four groups: Core EDA (which includes the Galaxy Design Platform, the Discovery Verification Platform and its Field Programmable Gate Array (FPGA) design products); IP and System-Level Solutions; Manufacturing Solutions and Professional Services. In July 2012, it acquired Ciranova. In October 2012, it acquired EVE. On November 30, 2012, the Company acquired SpringSoft. In February 2014, Synopsys Inc completed the acquisition of Target Compiler Technologies.
On September 2, 2010, the Company acquired Virage Logic Corporation. In October 2010, the Company acquired Optical Research Associates. In September 2011, the Company acquired nSys Design Systems Private Limited (nSys). In October 2011, the Company acquired Extreme DA. In January 2012, the Company acquired ExpertIO, Inc. In February 2012, the Company acquired Magma Design Automation Inc.
Core EDA products
The Company offers a number of Core EDA products to address the process. Its Core EDA products fall into the suites, which included the Galaxy Design Platform, which includes tools to design an integrated circuit; the Discovery Verification Platform, which includes tools to verify that an integrated circuit behaves! as intended, and the FPGA design products. Its Galaxy Design Platform provides its customers with a single, integrated chip design solution, which includes individual products and incorporates common libraries and consistent timing, delay calculation and constraints throughout the design process. The platform allows designers the flexibility to integrate internally-developed and third-party tools. With this advanced functionality, common foundation and flexibility, its Galaxy Design Platform reduces design times; decrease integration costs and minimize the risks inherent in advanced, integrated circuit designs. Its products span both digital and analog/mixed-signal designs.
The products included in the Galaxy Design Platform are the IC Compiler physical design solution, Design Compiler logic synthesis product, Galaxy Custom Designer physical design solution for analog/mixed-signal designs, PrimeTime/PrimeTime SI timing analysis products, StarRC product for ext raction, and the Hercules and IC Validator physical verification product family. The Lynx Design System is a production-ready chip implementation environment that combines a Galaxy-based design flow, graphical user interface (GUI)-based runtime automation, design metrics capture and reporting, and utilities that automate the configuration of pre-validated foundry data. The Lynx Design System helps customers improve their productivity and optimally deploy Synopsys tools and methodologies.
The Company’s Discovery Verification Platform is an integrated portfolio of functional, analog/mixed-signal, formal and low-power verification products. The platform includes its simulation and verification products and design-for-verification methodologies, and provides a consistent control environment to help improve the speed, breadth and accuracy of its customers’ verification efforts. The Discovery Verification Platform’s components support industry standards and spa n both digital and analog/mixed-signal designs. The principa! l product! s included in the Discovery Verification Platform are the VCS comprehensive RTL verification solution, Formality formal verification sign-off solution, NanoSim FastSPICE circuit simulation and analysis product, high-speed interface module (HSIM) hierarchical FastSPICE circuit simulation and analysis product, HSPICE circuit simulator, and CustomSim circuit simulation solution. FPGAs are chips that can be customized or programmed to perform a specific function after they are manufactured.
Intellectual Property (IP) and System-Level Solutions
Synopsys is a provider of high-quality, silicon-proven IP solutions for system-on-chip (SoC) designs. The broad DesignWare IP portfolio includes high quality solutions for widely used interfaces such as universal serial bus (USB), PCI Express, double data rate (DDR), Ethernet, serial advanced technology attachment (SATA) and high-definition multimedia interface (HDMI). In addition, Synopsys offers analog IP for h igh-definition video, analog-to-digital data conversion and audio. With its recent acquisition of Virage Logic Corporation, we added embedded memories, including static random access memory (SRAMs) and non-volatile memory, logic libraries, embedded test and repair IP and configurable processor cores, to its IP portfolio.
Synopsys has a portfolio of tools, models and services for the system-level design of SoCs. Primary system-level products include Platform Architect for architectural optimization, SPW and System Studio for algorithm design, Processor Designer for custom processor design, and Synphony Model and C Compiler for High Level Synthesis. In addition to these tools for the system-level design of SoCs, its portfolio includes prototyping tools for hardware verification, software development and hardware-software integration. With FPGA-based prototyping systems (HAPS), designers can speed embedded software development by three to six months with near real runtime speeds and real world interfaces, such as its pre-t! ested Des! ignWare IP components. The HAPS hardware systems are a modular, scalable and accurate way to model a chip. Its virtual prototyping solutions enable software engineers to start SoC and application software up to twelve months before traditional methods.
The Company’s Manufacturing Solutions products and technologies address this problem by introducing manufacturability and yield considerations early in the design process, thereby improving yields. Some of its Manufacturing Solutions address mask-making and yield enhancement of very small-geometry integrated circuits, as well as high-level modeling of physical effects within the integrated circuit. Its Manufacturing Solutions include the Technology-CAD (TCAD) device modeling products, Proteus OPC optical proximity correction (OPC) products, CATS mask data preparation product and yield management solutions, including odyssey and recipe manager and editor (RME), and yield exp lorer.
Professional Services and Training
Synopsys provides consulting and design services that address all phases of the SoC development process. These services assist Synopsys customers with new tool and methodology adoption, chip architecture and specification development, functional and low power design and verification, and physical implementation and signoff. It also provides a range of expert training and workshops on its latest tools and methodologies.
- [By Anna Prior]
Synopsys Inc.’s(SNPS) fiscal fourth-quarter profit nearly doubled on a top-line increase driven by growth in the company’s time-based license revenue. However, the company’s guidance for the current quarter came in below Wall Street expectations.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Synopsys (Nasdaq: SNPS ) , whose recent revenue and earnings are plotted below.
Top Low Price Stocks To Invest In Right Now: Celanese Corporation (CE)
Celanese Corporation, a technology and specialty materials company, engages in manufacture and sale of value-added chemicals, thermoplastic polymers, and other chemical-based products. It operates through four business segments: Advanced Engineered Materials, Consumer Specialties, Industrial Specialties, and Acetyl Intermediates. The Advanced Engineered Materials segment offers specialty polymers for application in automotive, medical, and electronics products, as well as other consumer and industrial applications. The Consumer Specialties segment provides cellulose acetate flake, film, and tow that are primarily used in filter products applications; Sunett, a sweetener; and food protection ingredients, such as sorbates and sorbic acid for the food, beverage, and pharmaceutical industries. The Industrial Specialties segment produces emulsions and ethylene vinyl acetate (EVA) performance polymers. Its emulsions products are used in applications, such as paints and coatings, adhesives, construction, glass fiber, textiles, and paper; and EVA performance polymers are used in flexible packaging films, lamination film products, hot melt adhesives, medical products, automotive, carpeting and photovoltaic cells. The Acetyl Intermediates segment offers acetyl products, including acetic acid, vinyl acetate monomer, acetic anhydride, and acetate esters for use as starting materials for colorants, paints, adhesives, coatings, and medicines. It also provides organic solvents and intermediates for pharmaceutical, agricultural, and chemical products. The company offers its products directly, as well as through distributors and electronic marketplaces in North America, Europe, Africa, the Asia-Pacific, and South America. Celanese Corporation was founded in 2004 and is headquartered in Dallas, Texas.
- [By Magic Diligence]
Given this fact, and the fact that consumer electronics (CE) is a cyclical industry, flash supply and demand balance is very tenuous. Frantic production to catch up to demand often leads to dramatic over-supply when the CE market cools off. One needs only to look at SanDisk’s financials to see this. The company swung from a $917 dollar operations loss in 2008 to a $1.5 billion dollar profit in 2011, and which was then cut in half to just a $700 million profit the following year!
- [By Monica Gerson]
Celanese (NYSE: CE) is estimated to report its Q3 earnings at $1.04 per share on revenue of $1.59 billion.
Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets
- [By Travis Hoium]
What: Shares of chemical maker Celanese (NYSE: CE ) jumped as much as 16% today after the company released earnings.
So what: Revenue fell slightly in the first quarter, to $1.61 billion, but adjusted earnings per share jumped 44%, to $1.14. Revenue was in line with expectations, and earnings crushed the $0.79 that analysts expected.
- [By Eric Volkman]
Celanese (NYSE: CE ) will have to pony up a significantly higher amount of money for its shareholder payouts. The company has declared a common stock dividend of $0.18 per share, to be paid on August 15 to shareholders of record as of August 5. That amount is exactly double the company’s previous distribution of $0.09.
Top Low Price Stocks To Invest In Right Now: Pharmaxis Ltd (PXS)
Pharmaxis Ltd is a pharmaceutical company that researches, develops and commercializes therapies for undertreated respiratory diseases. Its therapeutic interests include lung diseases such as cystic fibrosis, bronchiectasis and asthma, as well as chronic obstructive pulmonary diseases such as chronic bronchitis and pulmonary fibrosis. The Company’s products include Aridol and Bronchitol. The Company’s Aridol product is a lung function test. The product is designed to identify twitchy or hyper-responsive airways and to assist in diagnosing and managing asthma. Aridol is approved for sale in Australia, European countries, South Korea and the United States. is a drug designed to reduce the amount of mucus build-up in the lungs of patients suffering from chronic respiratory conditions. The Company develops Bronchitol for diseases including cystic fibrosis, bronchiectasis and chronic bronchitis. Advisors’ Opinion:
- [By Trista Kelley]
Science in Sport Ltd. broke away from its parent company, Provexis Plc (PXS), and began trading today after an initial public offering as the maker of nutritional sports gels rides a surge in Britain’s Lycra-clad cyclists.
Top Low Price Stocks To Invest In Right Now: Evolva Holding SA (EVE)
Evolva Holding SA (Evolva) discovers and provides ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create small molecule compounds and their production routes. The Company’s nutrition and consumer products include Pomecins, saffron, stevia, vanilla and resveratrol. The Company’s pharmaceuticals products include EV-077 and EV-035. In pharmaceuticals, the Company focuses on oral, small molecule drugs with application in complications of diabetes and infectious diseases. Pomecins are Evolva’s compounds. Evolva is focused on two members of the family – Pomecin A and Pomecin B. EV-035 is a bacterial type II topoisomerase inhibitor. Evolva is developing EV-077 for the treatment of diabetic complications. It is an oral, small molecule compound, belonging to a structural class. Advisors’ Opinion:
- [By Glenwoods]
Earlier this year the giant food processor, Cargill, partnered with the small Swiss company, Evolva (SIX:EVE), which was developing its own stevia-based fermentation process, also in the pilot stage. As noted earlier in the article, Cargill is in a partnership with Coca-Cola for Truvia, the bestselling stevia product on the market. The success of the Cargill/Evolva partnership could have big implications not just for Cargill and Coca-Cola, but also on the entire stevia and sweetener market. I further believe the success of the partnership could have a major impact on Stevia First. If Cargill’s fermentation method produces a better tasting stevia product at a lower cost it would give Coca-Cola a considerable advantage over the other beverage bottlers, food manufacturers, and stevia producers. Such an outcome would force these companies to scramble to find a similar method in order to compete. There would be a very good chance that rival companies, in order to stay in the game, would have to turn to the other company developing a fermentation-based stevia product– Stevia First. If that happens Stevia First’s value would rise considerably.
Top Low Price Stocks To Invest In Right Now: Geely Automobile Holdings Ltd (GELYF.PK)
Geely Automobile Holdings Limited is an investment holding company. The Company, along with its subsidiaries, is engaged in the research, production, marketing and sales of sedans and related automobile components in the People’s Republic of China (PRC). The Company operates in two segments: automobiles and related parts and components segment, engaged in the manufacture and sale of automobiles, automobile parts and related automobile components, and gearboxes segment, engaged in the manufacture and sale of gearboxes. The Company’s subsidiaries include Centurion Industries Limited, Value Century Group Limited, Geely International Limited, Zhejiang Fulin Guorun Automobile Parts & Components Co., Ltd., Linkstate Overseas Limited, Luckview Group Limited and Luck Empire Investment Limited, among others. Advisors’ Opinion:
- [By Elliott Gue]
This so-called One Ford initiative involved the US$2.3 billion sale of Jaguar and Land Rover to Tata Motors (TTM) and the US$1.6 billion divestment of Volvo to Geely Automobile Holdings (GELYF.PK). After selling the majority of its stake in Mazda Motor Corp (MZDAY.PK) and discontinuing Mercury, Ford Motor Company’s portfolio consists of its eponymous mass-market brand and the higher-end Lincoln.
Top Low Price Stocks To Invest In Right Now: Broadcom Corporation(BRCM)
Broadcom Corporation designs and develops semiconductors for wired and wireless communications. It provides a portfolio of system-on-a-chip (SoC) and software solutions for the manufacturers of computing and networking equipment, digital entertainment and broadband access products, and mobile devices, which enable the delivery of voice, video, data, and multimedia content to the home, office, and mobile environment. Its broadband communications products include cable modem SoCs; femtocell SoCs; MPEG/AVC/VC-1 encoders and transcoders; xDSL, passive optical network, and cable modem customer premises equipment and central office solutions; powerline networking SoCs; digital cable, direct broadcast satellite, terrestrial, and Internet protocol (IP) set-top box integrated receiver demodulators; high definition television and standard definition TV SoCs; and Blu-ray disc SoCs. The company?s mobile and wireless products comprise Wi-Fi and Bluetooth SoCs, wireless connectivity com bo chips, global positioning system SoCs, multimedia processors, applications processors, power management units, VoIP SoCs, mobile TV SoCs, and near field communications tags. Its infrastructure and networking products include Ethernet copper transceivers, Ethernet controllers and switches, backplane and optical front-end physical layer devices, security processors and adapters, and broadband processors. The company markets and sells its products through direct sales force, distributors, and manufacturers? representatives in the United States, as well as through regional offices, and a network of independent distributors and representatives in Asia, Australia, Europe, and North America. The company was founded in 1991 and is headquartered in Irvine, California.
- [By Marc Bastow]
Global semi-conductor solutions provider Broadcom (BRCM) raised its quarterly dividend 9.1% to 12 cents per share, payable on Mar. 3 to shareholder of record as of Feb. 14.
BRCM Dividend Yield: 1.59%
- [By Paul Ausick]
Short interest in Broadcom Corp. (NASDAQ: BRCM) rose 17.3% to 12.33 million shares. That is 2.2% of the total float. Broadcom is scheduled to report results on Thursday, and analysts estimate EPS at $0.57 on revenues of $2.02 billion. Both figures are below last year’s totals.
- [By Volcano Steve]
Other companies such as TriQuint (TQNT) and Broadcom (BRCM) are reporting results with "strong mobile demand" and "higher-than-anticipated sales of cellular system-on-chip (SOC) and touch controllers." More famously, Apple (AAPL) has announced record sales for its ARM-inside iPhone 5S model introduced last month. Investors and analysts already knew that ARM reports royalty revenue a quarter in arrears, so any gains from iPhone 5S sales will not start to be seen until ARM´s next quarterly report and were not expected to be a factor in this report.
- [By WALLSTCHEATSHEET]
Broadcom provides wireless and wired semiconductor technologies to businesses and consumers worldwide. A recent earnings release has investors disappointed with the company. The stock has struggled in recent years and is currently trading near lows for the year. Over the last four quarters, earnings have decreased while revenues have increased, which has left investors to expect more from the company. Relative to its peers and sector, Broadcom has been a weak year-to-date performer. WAIT AND SEE what Broadcom does this coming quarter.
Top Low Price Stocks To Invest In Right Now: Andatee China Marine Fuel Services Corporation(AMCF)
Andatee China Marine Fuel Services Corporation, through its subsidiaries, engages in the production, storage, distribution, and wholesale purchase, and sale of blended marine fuel oil for cargo and fishing vessels primarily in Tianjin City, and Liaoning, Shandong, and Zhejiang Provinces in the People?s Republic of China. It sells its products through distributors, as well as to retail customers. The company was founded in 1997 and is based in Dalian, the People?s Republic of China.
- [By Roberto Pedone]
Another under-$10 energy player that’s starting to move within range of triggering a big breakout trade is Andatee China Marine Fuel Services (AMCF), which is engaged in the production, storage, distribution and wholesale purchases and sales of blended marine fuel oil for cargo and fishing vessels. This stock has been in play with the bulls so far in 2013, with shares up big by 180%.
If you take a look at the chart for Andatee China Marine Fuel Services, you’ll notice that this stock has been uptrending strong over the last month and change, with shares moving higher from its low of 98 cents per share to its recent high of $1.69 a share. During that move, shares of AMCF have been making mostly higher lows and higher highs, which is bullish technical price action. That move is now starting to push shares of AMCF within range of triggering a big breakout trade above a key downtrend line.
Market players should now look for long-biased trades in AMCF if it manages to break out above some near-term overhead resistance levels at $1.69 to $1.80 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 215,352 shares. If that breakout hits soon, then AMCF will set up to re-test or possibly take out its next major overhead resistance levels at $1.98 to just above $2.20 a share. Any high-volume move above those levels will then give AMCF a chance to tag its 52-week high at $2.75 a share.
Traders can look to buy AMCF off any weakness to anticipate that breakout and simply use a stop that sits right around some key near-term support levels at $1.29 or at $1.15 a share. One can also buy AMCF off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Roberto Pedone]
Andatee China Marine Fuel Services (AMCF) is engaged in the production, storage, distribution and wholesale purchases and sales of blended marine fuel oil for cargo and fishing vessels. This stock closed up 4.1% to $1.27 in Thursday’s trading session.
Thursday’s Range: $1.22-$1.32
52-Week Range: $0.45-$2.75
Thursday’s Volume: 150,000
Three-Month Average Volume: 193,369
From a technical perspective, AMCF spiked sharply higher here with lighter-than-average volume. This move is quickly pushing shares of AMCF within range of triggering a major breakout trade. That trade will hit if AMCF manages to take out Thursday’s high of $1.32 to its 50-day moving average of $1.39 with high volume.
Traders should now look for long-biased trades in AMCF as long as it’s trending above some key near-term support levels at $1.15 or at $1.09 and then once it sustains a move or close above those breakout levels with volume that hits near or above 193,369 shares. If that breakout hits soon, then AMCF will set up to re-test or possibly take out its next major overhead resistance levels at $1.80 to $1.98. Any high-volume move above those levels will then give AMCF a chance to re-test its 52-week high at $275.
Top Low Price Stocks To Invest In Right Now: Western Asset Mortgage Capital Corp (WMC)
Western Asset Mortgage Capital Corporation is focused on investing in, financing and managing primarily residential mortgage-backed securities (RMBS), which are not issued or guaranteed by a United States Government agency or federally chartered corporation, or non-Agency RMBS. The Company also focuses on investing in commercial mortgage-backed securities (CMBS), and other asset-backed securities (ABS), as well as RMBS for which a United States Government agency or federally chartered corporation guarantees payments of principal and interest on the securities, or Agency RMBS.
The Company is managed and advised by Western Asset Management Company. As of June 12, 2009, the Company had not made any investments.
- [By Lawrence Meyers]
Today, we’re looking at three dividend stocks with sky-high dividend yields to see whether they’re safe.
Western Asset Mortgage Capital Corporation (WMC)
Dividend Yield: 19.8%
- [By Rick Munarriz]
Western Asset Mortgage Capital (NYSE: WMC ) is also beefing up its yield. The REIT that snaps up residential mortgage-backed securities and shells out most of the housing payments to its stakeholders is boosting its quarterly rate by 5% to $0.95 a share.
Top Low Price Stocks To Invest In Right Now: Response Genetics Inc.(RGDX)
Response Genetics, Inc., a life sciences company, engages in the research, development, marketing, and sale of clinical diagnostic tests and pharmacogenomic tests for use in the treatment of cancer primarily in the United States, Asia, and Europe. The company develops genetic tests that measure predictive factors for tumor response in tumor tissue samples. It offers tests for non-small cell lung cancer under the ResponseDX: Lung trade name; colorectal cancer under the ResponseDX: Colon trade name; and gastric and gastroesophageal cancer under the ResponseDX: Gastric trade name. The company also develops tests for other types of cancer that identify genetic profiles of tumors that recur after surgery. Response Genetics, Inc. offers its products through its sales force to community based oncologists, hospitals, and physician offices. In addition, it provides pharmacogenomic testing services to pharmaceutical companies. The company was formerly known as Bio Type, Inc. and cha nged its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
- [By Monica Gerson]
Response Genetics (NASDAQ: RGDX) slipped 9.47% to $1.34 after the company reported Q4 results. The company posted a quarterly net loss of $3.2 million, or $0.09 per share, versus a year-ago net loss of $0.5 million, or $0.01 per share.
Top Low Price Stocks To Invest In Right Now: Oxygen Biotherapeutics Inc.(OXBT)
Oxygen Biotherapeutics, Inc., a development stage company, engages in developing biotechnology products that deliver oxygen to target tissues in the body in the United States. The company primarily offers Oxycyte, a perfluorcarbon (PFC) based oil in water emulsion that carries oxygen and is been formulated for intravenous delivery for the treatment of traumatic brain injury, spinal cord injury, and decompression sickness; and other PFC-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. It also provides Dermacyte line of topical cosmetic products that promote the appearance of skin health and other cosmetic benefits; and Wundecyte, a wound-healing gel. It markets its Dermacyte line of products through buydermacyte.com; and to dermatologists and medical spas with a combination of in-house sales, independent sales agents, and distributors. The company was formerly known as Synthetic Blood International, Inc. and changed its n ame to Oxygen Biotherapeutics, Inc. in June 2008. Oxygen Biotherapeutics, Inc. was founded in 1967 and is based in Morrisville, North Carolina.
- [By Bryan Murphy]
To say that Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) has made its presence known over the past three weeks would be an understatement. It would be more accurate and fairer to say OXBT been an “in your face” kind of name that you couldn’t look past even if you wanted to. Rather than continue to sidestep it, care to stop, invest two minutes of time, and get the Q&D version of what’s really going on here? If so, read on.
- [By Paul Ausick]
Stocks on the Move: GT Advanced Technologies Inc. (NASDAQ: GTAT) is up 20.5% at $10.10 after earnings and signing deal to supply Apple Inc. (NASDAQ: AAPL) with sapphire glass. Marvell Technology Group Ltd. (NASDAQ: MRVL) is up 8.5% at $13.03 following reports of an investment by KKR & Co. (NYSE: KKR). Oxygen Biotherapeutics Inc. (NASDAQ: OXBT) is up 62.7% at $8.38 along with other biotech stocks making big moves today.
- [By John Udovich]
Yesterday, small cap Oxygen Biotherapeutics, Inc (NASDAQ: OXBT) surged 87.33% to $2.81 after published results showed that its levosimendan was associated with reduced mortality, meaning its probably time to do a reality check about the stock as well as look at its performance against that of industry benchmarks like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
- [By Lauren Pollock]
Oxygen Biotherapeutics Inc.(OXBT) said it agreed to buy about $4.8 million in assets from Phyxius Pharma that treat cardiac-surgery patients. Shares of Oxygen Biotherapeutics rose.